Note: This consent is given subject to the following conditions:

• Rilutek Tablets can only be prescribed by authorised prescribers where the prescribing decision is taken in collaboration with, or following consultation with, physicians who care for patients with Motor Neuron Disease, neurologists and palliative care physicians.
• Rilutek Tablets can only be used by patients with vital capacity greater than 60%.

Also note: This renewed consent is valid for two years from 11 November 2019.